AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.
FAIL · Does not pass the screen
7.35 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
AtaiBeckley Inc. holds its Accumulation at $7.35. Consolidating, no directional conviction, held for 16 days.
As held on the ledger · 2026-08-27
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 16 days
Price at the screen
$7.35
Valuation
N/A trailing · -15.00 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.55
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.71%
Below 33%
Interest-bearing debt is just 0.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
58.33%
Below 33%
Interest-bearing cash and securities are 58.3% of assets, above the one-third limit.
Fail
Receivables
29.37%
Below 49%
Money owed to the company is 29.4% of assets, under the 49% limit.
Pass
Revenue purity
36.15%
Below 5%
36.1% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 8.8% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus Hold. The average target sits +9% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Mental Health Biotech Still Years From Profits
Picture a lab racing to turn psychedelic compounds into approved depression treatments. The science might one day help patients, yet the numbers show a company still burning cash with no revenue growth and no profits in sight. Opportunity rating sits at none because the financial picture fails every basic test of a viable business.
Revenue fell 39 percent last year while profit margins remain zero and return on equity sits at negative 378 percent. Forward earnings sit in deeply negative territory and no economic moat is visible. Analyst targets may point higher, but those views ignore how clinical stage biotechs routinely dilute shareholders for years before any product reaches market.
Risks centre on trial failures, regulatory delays and repeated capital raises that erode value. Even with an ethical screen pass the lack of commercial traction and negative cash flow leave too much uncertainty for any position. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ATAI trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-08-22Accumulation$7.23+0.1%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it strong buy, with a mean price target of $14.
2026-07-22Accumulation$7.22+84.2%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 84.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it strong buy, with a mean price target of $14.
2026-07-18Accumulation$3.92+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 72%. Our forward projection puts the odds of a 10% gain over the next month near 40%. The street (12 analysts) rates it strong buy, with a mean price target of $14.
2026-07-03Accumulation$3.92+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Accumulation$3.92Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
